BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.17.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261103
DTEND;VALUE=DATE:20261124
DTSTAMP:20260709T125124Z
CREATED:20260709T125124Z
LAST-MODIFIED:20260709T125124Z
UID:43917-1793664000-1795478399@www.pharmajournalist.com
SUMMARY:10th Dermatology Drug Development Summit
DESCRIPTION:10th Dermatology Drug Development Summit – Discovering\, Developing & Commercializing Next-Generation Inflammatory Skin Disease Therapeutics – November 3-5\, 2026 | Boston\, MA \nThe 10th Dermatology Drug Development Summit returns in 2026 as the leading premier forum dedicated to advancing the discovery\, development\, and commercialization of innovative therapies for inflammatory skin disease. \nMarking a decade of convening the field’s most influential voices\, this year’s summit arrives at a pivotal moment: As competition intensifies across atopic dermatitis and psoriasis\, developers are under growing pressure to demonstrate meaningful differentiation\, accelerate development timelines and identify the next generation of high-value opportunities beyond today’s established targets and therapies. \nDesigned as an intimate\, discussion-led forum\, the summit brings together more than 90 experts spanning discovery\, translational medicine\, preclinical development\, clinical strategy\, medical affairs\, and commercial functions. \nThe meeting provides a unique opportunity to benchmark emerging science\, evaluate novel targets\, and share practical lessons from across the dermatology pipeline. \nAttendees will hear from 40+ senior leaders representing major pharmaceutical companies\, innovative biotechs\, academic research centers\, and patient advocacy organizations\, with representation from AbbVie\, Galderma\, Merck\, SUN Pharma\, Eli Lilly\, UNION Therapeutics and others. \nThis year’s agenda features dual content tracks including Discovery & Preclinical and Clinical & Commercial. \nNew additions include a Pre-Conference Workshop Day\,  offering interactive deep dives into two of dermatology’s fastest-growing areas of innovation: hidradenitis suppurativa\, exploring strategies to drive earlier intervention and disease modification\, and rare & ultra-rare inflammatory skin diseases\, examining how developers can generate meaningful evidence\, overcome translational challenges and unlock scalable opportunities across underserved patient populations. \nWith 10+ hours of in-person networking\, the summit fosters meaningful collaboration among scientists\, clinicians\, executives\, and decisionmakers working to discover\, develop and commercialize the next wave of precision therapeutics. \nFor organizations committed to shaping the future of inflammatory skin disease drug development\, the Dermatology Drug Development Summit remains the essential annual meeting to align on emerging science\, evolving standards of care\, and the path to impactful patient outcomes. \nFind out more about the 10th Anniversary Edition of the Dermatology Drug Development Summit: https://ter.li/rcr0mcj
URL:http://www.pharmajournalist.com/event/10th-dermatology-drug-development-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261113
DTSTAMP:20260703T090227Z
CREATED:20260703T090227Z
LAST-MODIFIED:20260703T090227Z
UID:43883-1794268800-1794527999@www.pharmajournalist.com
SUMMARY:9th RNA-Targeted Drug Discovery & Development Summit
DESCRIPTION:The 9th RNA-Targeted Drug Discovery & Development Summit returns to Boston\, MA\, on November 10–12\, 2026\, as the industry’s only dedicated meeting focused exclusively on RNA-targeted small molecules\, bringing together leading minds from biotech\, pharma and academia to advance the next generation of RNA-focused therapeutics. \nAs momentum continues to build across the field\, driven by recent clinical progress and increasing investment in RNA-targeted approaches\, the summit will explore the latest advances in direct RNA binding\, splice modulation\, RNA degradation\, covalent translation inhibition\, epitranscriptomic regulation and condensate biology. Attendees will gain valuable insights into how researchers are overcoming historic challenges in RNA druggability to develop new treatments for oncology\, rare genetic diseases and neurodegenerative disorders. \nA refreshed 2026 agenda will feature expert-led presentations\, case studies\, panel discussions and interactive workshops covering functional RNA target selection\, structure-guided design\, productive chemical space and emerging RNA-targeting technologies. Delegates will also discover practical strategies for improving screening approaches\, measuring selectivity\, validating targets and accelerating translation from discovery into clinical development. \nThe summit is expected to welcome 80+ RNA-targeted drug discovery experts and 22+ world-class speakers\, including representatives from PTC Therapeutics\, AstraZeneca\, Sanofi\, ReviR Therapeutics\, Remix Therapeutics\, Arrakis Therapeutics\, Dewpoint Therapeutics and Syrna Therapeutics. Through dedicated networking opportunities and collaborative discussions\, attendees will connect with the scientists\, innovators and decision-makers shaping the future of RNA-targeted medicines. \nWhether you are focused on RNA biology\, medicinal chemistry\, drug discovery\, translational research or therapeutic development\, this summit offers an unparalleled opportunity to access cutting-edge data\, exchange ideas with pioneers in the field and help drive the next wave of innovation in RNA-targeted small molecule therapeutics. As the field continues to mature\, the 9th RNA-Targeted Drug Discovery & Development Summit remains the must-attend forum for staying at the forefront of RNA drug discovery.
URL:http://www.pharmajournalist.com/event/9th-rna-targeted-drug-discovery-development-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261113
DTSTAMP:20260709T124430Z
CREATED:20260709T124339Z
LAST-MODIFIED:20260709T124430Z
UID:43911-1794268800-1794527999@www.pharmajournalist.com
SUMMARY:9th Lab Asset & Facility Management Summit
DESCRIPTION:The 9th Lab Asset & Facility Management (LAFM) Summit 2026 is the leading industry forum dedicated to helping pharmaceutical and biotech organizations optimize lab operations\, asset management\, facilities\, engineering\, and research infrastructure. Taking place in Boston\, MA from November 10–12\, 2026\, the flagship event brings together 190+ senior leaders and decision-makers responsible for creating efficient\, resilient\, and high-performing R&D environments. \nAs scientific research becomes increasingly complex and organizations face growing pressure to do more with less\, LAFM provides a unique platform to explore practical strategies that improve operational efficiency\, maximize asset performance\, strengthen cross-functional collaboration\, and ultimately give scientists more time to focus on breakthrough research. \nJoin us to gain actionable insights through over 28 real-world case studies\, interactive discussions\, peer-to-peer benchmarking\, and hands-on workshops designed to address the most pressing challenges facing lab operations and facility management teams today. The agenda features dedicated content covering both laboratory operations and site-wide management\, helping attendees discover proven approaches to streamlining workflows\, improving maintenance strategies\, enhancing asset visibility\, and building more future-ready research environments. \nThe 2026 agenda also introduces innovative networking and learning formats\, including the LAFM Exchange and the R&D Operations Action Day\, giving participants more opportunities to engage with peers\, share experiences\, and leave with practical frameworks they can implement immediately within their own organizations. \nBringing together experts from leading organizations including Pfizer\, Takeda\, Novartis\, Regeneron\, Sanofi\, Boehringer Ingelheim\, Gilead Sciences\, and Eli Lilly\, LAFM offers an unrivalled opportunity to connect with the people shaping the future of laboratory and facility operations across the life sciences industry. Whether your goal is to increase operational efficiency\, improve facility performance\, support scientific teams more effectively\, or benchmark your strategy against industry leaders\, LAFM is the place to learn\, connect\, and drive meaningful impact across your organization. \nTo know more visit: https://ter.li/mnzyk67w
URL:http://www.pharmajournalist.com/event/9th-lab-asset-facility-management-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261113
DTSTAMP:20260709T143647Z
CREATED:20260709T143647Z
LAST-MODIFIED:20260709T143647Z
UID:43936-1794268800-1794527999@www.pharmajournalist.com
SUMMARY:World Cell & Gene Therapy Summit South Korea
DESCRIPTION:South Korea’s cell and gene therapy landscape is highly dynamic\, as observed from regulatory approvals\, clinical trial progress\, and manufacturing activity\, from over 150 companies in active drug development. Additionally\, with global pharma including Bayer\, Novartis and more seeing strategic investments into the CGT space within South Korea\, greater opportunities for scientific innovation and technology advancement are yet to come. \nThe inaugural World Cell & Gene Therapy Summit South Korea is an exclusive opportunity to connect with global pharma and leading Korean biotech showcasing the latest trends in autologous\, allogeneic\, in vivo\, and gene editing therapies to help you identify gaps within your programs and set the roadmap of CGT development in 2026/2027. \nOne Pass\, Two Events: Part of the World Advanced Therapeutics Summit South Korea organized by Hanson Wade\, this event offers a platform for cross-learning and connections with experts working in RNA and vaccine development and together establish South Korea as a global hub for advanced biopharma innovation.
URL:http://www.pharmajournalist.com/event/world-cell-gene-therapy-summit-south-korea/
LOCATION:Grand Hyatt Incheon\, 208 Yeongjonghaeannam-ro 321beon-gil\, Jung-gu\, Incheon\, South Korea
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261113
DTSTAMP:20260709T144427Z
CREATED:20260709T144427Z
LAST-MODIFIED:20260709T144427Z
UID:43942-1794268800-1794527999@www.pharmajournalist.com
SUMMARY:2nd World RNA-Based Therapeutics & Vaccines Summit South Korea
DESCRIPTION:Driven by South Korea’s government making strategic investments in mRNA platforms and growing collaboration between global pharma and local biotech innovators\, the field is experiencing renewed development momentum. This is placing the region as a key hotspot for global mRNA innovation and interest. \nUniquely positioned as the industry’s most comprehensive biopharma forum\, the 2nd World RNA-Based Therapeutic & Vaccine Summit South Korea brings together global and local leaders to share first-hand insights into cutting-edge mRNA modalities\, delivery technologies\, and manufacturing excellence\, to progress mRNA medicines to patients faster. \nOne Pass\, Two Events: Part of the World Advanced Therapeutics Summit South Korea organized by Hanson Wade\, this event offers a platform for cross-learning and connections with experts working in cell and gene therapies and together establish South Korea as a global hub for advanced biopharma innovation.
URL:http://www.pharmajournalist.com/event/2nd-world-rna-based-therapeutics-vaccines-summit-south-korea/
LOCATION:Grand Hyatt Incheon 208 Yeongjonghaeannam-ro\, 321 Beon-gil\, Yeongjong-gu\, 23358\,  Incheon South Korea
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR